Oncogenicity Variant Interpreter (OncoVI): oncogenicity guidelines implementation to support somatic variants interpretation in precision oncology

Maria Giulia Carta,Lars Toegel,Annett Hoelsken,Christoph Schubart,Heinrich Sticht,Robert Stoehr,Silvia Spoerl,Norbert Meidenbauer,Arndt Hartmann,Paolo Magni,Florian Haller,Fulvia Ferrazzi

DOI: https://doi.org/10.1101/2024.10.10.24315072

2024-10-10

Abstract:Background In precision oncology, the accurate and reproducible classification of variant oncogenicity is fundamental for therapy decision making. In 2022, a set of guidelines for the classification of oncogenicity of somatic variants in cancer were defined by the Clinical Genome Resource, the Cancer Genomics Consortium, and the Variant Interpretation for Cancer Consortium. However, to date an implementation that automates the evaluation of these criteria does not exist. Furthermore, for the majority of the criteria, the interpretation of the criterion-associated textual indication and the choice of publicly available resources to gather criterion-supporting information depends on the user. Thus, the risk of a variant being classified differently by independent laboratories is relevant, with implications for the management of patient care. Methods Here, we developed Oncogenicity Variant Interpreter (OncoVI), a fully-automated Python-based implementation of the oncogenicity guidelines. First, each criterion was interpreted and publicly available resources were identified to be utilised as reference. Then, criteria were implemented in OncoVI and the information reported by the associated resources were integrated. OncoVI is part of a broader Python-framework that, starting from the genomic position of the variant, automatically performs functional annotation, collects the available evidence from the reference resources, and provides a classification of oncogenicity. Results On the set of 93 somatic variants provided by the guidelines OncoVI achieved an overall accuracy of 80%, with a sensitivity of 88% in the classification of Oncogenic/Likely Oncogenic variants. On a real-world data set of 7,802 variants from 557 patients previously evaluated within the Molecular Tumour Board (MTB) Erlangen, an agreement of 79% was observed between the oncogenicity classification of OncoVI and the MTB pathogenicity assessment. In addition, the pathogenicity classification of 135 variants of the MTB data set was re-assessed by expert biologists adhering solely to the oncogenicity guidelines. This re-evaluation confirmed the validity of OncoVI"s interpretation of the resources chosen as reference, but it also underlined the ability of experts in solving conflicting evidence. Conclusions Taken together, OncoVI provides an effective implementation of the oncogenicity guidelines, thus facilitating their adoption and supporting the reproducible and harmonised oncogenicity classification of somatic variants between institutions.

Genetic and Genomic Medicine

What problem does this paper attempt to address?

The paper attempts to address the issue of the lack of automated tools to support the classification of somatic variants' oncogenicity in precision oncology. Specifically:

- **Background Issue**: In precision oncology, accurately and reproducibly classifying the oncogenicity of somatic variants is crucial for treatment decisions. In 2022, the Clinical Genome Resource, Cancer Genomics Consortium, and Variant Interpretation for Cancer Consortium defined a set of guidelines for classifying the oncogenicity of somatic variants. However, there are currently no automated tools to implement these guidelines. Additionally, for most standards, the interpretation of textual instructions and the selection of publicly available resources to gather supporting information rely on the user, which may lead to inconsistent classification of the same variant across different laboratories, thereby affecting patient management.

- **Solution**: The research team developed the Oncogenicity Variant Interpreter (OncoVI), a fully automated Python tool that implements the oncogenicity guidelines. OncoVI can automatically perform functional annotation from genomic positions, gather evidence from reference resources, and provide a classification of oncogenicity. This helps to standardize and ensure consistency in the classification of somatic variant oncogenicity across different institutions.

Through the above methods, OncoVI provides an effective solution, enabling the widespread adoption of oncogenicity guidelines and supporting reproducible and consistent classification across different institutions.